DOCSLIB.ORG

Abstract Book 2012.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstract Book 2012.Indd SUPPLEMENT TO JOURNAL OF PSYCHOPHARMACOLOGY VOL 26, SUPPLEMENT TO ISSUE 8, AUGUST 2012 These papers were presented at the Summer Meeting of the BRITISH ASSOCIATION FOR PSYCHOPHARMACOLOGY 22 – 25 July, Harrogate, UK Indemnity The scientific material presented at this meeting reflects the opinions of the contributing authors and speakers. The British Association for Psychopharmacology accepts no responsibility for the contents of the verbal or any published proceedings of this meeting. BAP OFFICE 36 Cambridge Place Hills Road Cambridge CB2 1NS bap.org.uk Aii CONTENTS Abstract Book 2012 Abstracts begin on page: SYMPOSIUM 1 A1 Drugs as tools in neuropsychiatry: Ketamine (S01-S04) SYMPOSIUM 2 A2 New tricks for old drugs: Opiates, addiction and beyond (S05-S08) SYMPOSIUM 3 A3 Advances in understanding brain corticosteroid responses to stress: relevance to depression (S09-S12) SYMPOSIUM 4 A5 Cognitive impairment in depression: A target for treatment? (S13-S16) SYMPOSIUM 5 A6 New treatment strategies for targeting drug addictions – A translational perspective (S17-S20) SYMPOSIUM 6 A7 Functional imaging markers for monitoring treatment: Mechanisms and efficacy (S21-S24) SYMPOSIUM 7 A9 Schizophrenia Treatment: What’s wrong with it and what might work better (S25-S28) SYMPOSIUM 8 A10 Epigenetics and psychiatry - current understanding and therapeutic potential (S29-S32) SYMPOSIUM 9 A11 Rethinking the compulsive aspects of addiction: From bench to bedside (S33-S36) POSTERS Anxiety 1 (MA01-MA07) A13 Affective Disorders 1 (MB01-MB20) A16 Brain Imaging (MC01-MC12) A24 Cognition 1 (MD01-MD09) A29 Educational Psychopharmacology (ME01-ME05) A33 CONTENTS Aiii Abstract Book 2012 (continued) Abstracts begin on page: Schizophrenia 1 (MF01-MF13) A35 Substances of Abuse 1 (MG01-MG09) A40 Anxiety 2 (TA01-TA05) A44 Affective Disorders 2 (TB01-TB21) A46 Sleep (TC01-TC05) A54 Cognition 2 (TD01-TD10) A56 Neuropharmacology (TE01-TE07) A60 Schizophrenia 2 (TF01-TF11) A63 Feeding and Eating (TG01-TG03) A67 Substances of Abuse 2 (TH01-TH15) A68 Psychomotor Stimulants (TI01-TI03) A73 POSTDOCTORAL SYMPOSIUM A74 Neurodevelopmental models of psychiatric disease: back to the future (PD01-PD04) SHORT ORAL PRESENTATIONS Short Orals 1: New ways to model anxiety See abstracts MA01, MA05, MA04, MA07 Short Orals 2: Cognitive enhancement: From aspiration to realisation See abstracts TD06, SO01 (page A75), TD08, TF06 Short Orals 3: Cannabinoids: Toxic effects and treatment applications See abstracts TF04, MG03, MG05, MG04 GUEST LECTURE (GL1) A75 BAP PSYCHOPHARMACOLOGY AWARD WINNERS (PW1-PW3) A76 ABSTRACTS A1 S01 THE TRANSLATIONAL NEUROPHARMACOLOGY OF KETAMINE Deakin JFW, Neuroscience and Psychiatry Dept, Univ of Manchester, G907 Stopford Building Oxford Rd Manchester M13 9PT, [email protected] The acute psychotomimetic effects of drugs that block the ion-channel associated with the NMDA glutamate receptor such as phencyclidine and ketamine have been the focus of much research interest for several decades. More recently, therapeutic effects in depression have been reported that emerge after some hours after a single dose of ketamine. This presentation focuses on the use of ketamine to understand the mode of action of two novel drugs: minocycline for negative symptoms of schizophrenia (Chaudhry et al, J Psychopharmacol 2012 (in press)); and AZ 6765, a NMDA channel blocker for depression. The translational tools were electrophysiology and blood oxygenation level dependent (BOLD) MRI imaging of drug effects using pharmaco-MRI (phMRI). In electrophysiological studies in the rat, ketamine, like other NMDA channel-blockers, caused a marked activation of hippocampal and frontal cortical neuronal fi ring rate and desynchronisation of the predominant delta rhythm associated with α-chloralose anaesthesia. Minocycline pre-treatment completely prevented the desychronisation induced by ketamine without affecting the increased fi ring rate. Translational studies with ketamine point to a novel glutamatergic action of minocycline in facilitating integrative function in cortex. Depression has been associated with over-activity of the subgenual cingulate cortex (SCG) which normalises with recovery. An acute iv bolus infusion of ketamine was previously reported to decrease BOLD signal in SGC in healthy volunteers (Deakin JFW et al, Arch General Psychiat 2008; 65:154-64). We investigated whether AZD6765 and ketamine shared this effect in 60 depressed participants when administered as a slow intravenous infusion and whether SCG effects were associated with clinical outcome 24 and 7 days later. The study was carried out in Manchester and Oxford, UK. Against our prediction, no decreases following drug were seen in any region compared to saline. Instead both drugs gradually increased SGC BOLD signal during the infusion. SCG was the only area in which phMRI responses to drug correlated with improvement in Montgomery- Asberg mood ratings scale 24hrs and 7 days later. Interviewer-rated psychotic and dissociative symptoms were minimal and not statistically signifi cant after AZ6765 but statistically signifi cant after ketamine. Improvement in mood did not differ between active and placebo treatments. The results suggest that AZ6765 and ketamine have antidepressant - like effects on emotion processing in the brain, that these effects may be initiated by actions on the SGC, and that diminished NMDA glutamate neurotransmission is the immediate mechanism. Funding: AstraZeneca, Medical Research Council UK, Stanley Medical Research Institute S02 KETAMINE IN HEALTHY VOLUNTEERS AS A MODEL OF SCHIZOPHRENIA Fletcher PC, Psychiatry, Univ of Cambridge, Herchel Smith Bldg Addenbrooke’s Hospital, West Forvie Site Robinson Way, Cambridge, CB2 0SZ, [email protected] Introduction: Acute administration of the competitive NMDA antagonist, ketamine, to healthy people produces a complex array of perceptual, cognitive and motor changes that are strikingly redolent of early psychosis. The purpose of a drug model, however, should go beyond replicating key characteristics of a syndrome and should aim, in addition, to establish both construct and predictive validity. That is, it should be possible to show that the drug reproduces the key symptoms by acting on brain circuitry known to be disturbed in association with the syndrome and it should moreover be possible to show that the symptoms that it produces are related to, and predicted by, its underlying effects on brain and cognition. The work reported here explored these possibilities in the context of the ketamine model of psychotic symptoms and is based on the suggestion that these symptoms occur as a consequence of a derangement in prediction error-dependent learning. It is a model that appeals more broadly to the predictive coding model of psychosis. Methods: We used serial studies on overlapping participant groups. The aim was initially to defi ne neural markers for a specifi c prediction error-dependent learning process. Subsequently, these subjects participated in a placebo-controlled study of ketamine’s effects on perception, experience and cognitive performance. The central aim was to determine whether individual variability in neural responses to prediction error were predictive of individual vulnerability to the effects of subsequent ketamine administration. This would provide evidence of a link between a specifi c neural response, a cognitive process and a neurochemical perturbation in subjective experiences. Such a link would be valuable in assessing the validity of the cognitive model of psychosis underlying the experiment. Results: Frontal and striatal activity measured during the initial phase of testing covaried strongly with prediction error-dependent learning. Variations in these responses predicted the effects of ketamine on cognitive performance in learning tasks as well as the tendency of the drug to produce mild symptoms of psychosis. Conclusions: Administration of ketamine produces a constellation of perceptual and cognitive effects, as well as psychosis-like symptoms. As well as being strikingly redolent of early psychotic illness, these are related to alterations in prediction error-dependent learning processes. People in whom neural responses to such processes are greater appear to show increased vulnerability to the drug’s effects. This intimate relationship between process-specifi c neural responding and ketamine-related disturbance may offer important insights to the neurobiology of how psychotic symptoms emerge. S03 KETAMINE AND THE POTENTIAL ROLE FOR RAPID ACTING ANTIDEPRESSANTS Krystal JH, Psychiatry Yale University School of Medicine, 300 George St., Suite 901, New Haven, CT 06511 USA [email protected] There is a tremendous need for antidepressant treatments that work more rapidly and more effectively than available treatments. Our current antidepressant treatments (monoamine reuptake or metabolism modulators, lithium, ECT) have been in place for over 50 years. This presentation will review the path that let to the identifi cation of ketamine as the fi rst rapid onset antidepressant treatment. Ketamine is a short-acting NMDA glutamate receptor antagonist. A series of studies now demonstrate that a single intravenous dose of ketamine will produce reductions in depression severity within several hours and remission of depression in many patients within 24 hours. The antidepressant effects of a single dose of ketamine appear to last generally, from several days to several weeks. In light of evidence that suicidal ideation improves with
Load more

Recommended publications
  • (125I)Iodoazidococaine, a Photoaffinity Label for the Haloperidol-Sensitive Sigma Receptor (Cocaine/[3H]Cocaine Binding/Cocaine-Binding Protein) JOHN R
    Proc. Natl. Acad. Sci. USA Vol. 89, pp. 1393-1397, February 1992 Biochemistry (125I)Iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor (cocaine/[3H]cocaine binding/cocaine-binding protein) JOHN R. KAHOUN AND ARNOLD E. RuOHO* Department of Pharmacology, University of Wisconsin Medical School, Madison, WI 53706 Communicated by James A. Miller, October 8, 1991 (received for review July 10, 1991) ABSTRACT A carrier-free radioiodinated cocaine photo- cifically block the photolabeling ofthe DA transporter, it was affinity label, (-)-3-('25I)iodo-4-azidococaine [('25I)IACoc], not established whether cocaine bound directly to this protein has been synthesized and used as a probe for cocaine-binding or to an associated protein. Recently, the human NE trans- proteins. Photoaffinity labeling with 0.5 nM ('25I)IACoc re- porter has been expression-cloned as cDNA and overex- sulted in selective derivatization of a 26-kDa polypeptide with pressed in HeLa cells (13). The ability of cocaine to block the pharmacology of a sigma receptor in membranes derived [3H]NE uptake into these HeLa cells provides good evidence from whole rat brain, rat liver, and human placenta. Covalent that cocaine binds directly with this transporter. labeling of the 26-kDa polypeptide was inhibited by 1 FM Although cocaine has been shown to block the binding of haloperidol, di(2-tolyl)guanidine (DTG), 3-(3-hydroxyphenyl)- sigma ligands to rat and guinea pig brain membranes with N-(1-propyl)piperidine (3-PPP), dextromethorphan, and car- relatively low affinity, the nature and physiological impor- betapentane. Stereoselective protection of (125I)IACoc photo- tance of this interaction is not known.
    [Show full text]
  • Nietzsche and Psychedelics – Peter Sjöstedt-H –
    Antichrist Psychonaut: Nietzsche and Psychedelics – Peter Sjöstedt-H – ‘… And close your eyes with holy dread, For he on honey-dew hath fed, And drunk the milk of Paradise.’ So ends the famous fragment of Kubla Khan by the Romantic poet, Samuel Taylor Coleridge. He tells us that the poem was an immediate transcription of an opium-induced dream he experienced in 1797. As is known, the Romantic poets and their kin were inspired by the use of psychoactive substances such as opium, the old world’s common pain reliever. Pain elimination is its negative advantage, but its positive attribute lies in the psychedelic (‘mind- revealing’)1 state it can engender – a state described no better than by the original English opium eater himself, Thomas De Quincey: O just and righteous opium! … thou bildest upon the bosom of darkness, out of the fantastic imagery of the brain, cities and temples, beyond the art of Phidias and Praxiteles – beyond the splendours of Babylon and Hekatómpylos; and, “from the anarchy of dreaming sleep,” callest into sunny light the faces of long-buried beauties … thou hast the keys of Paradise, O just, subtle, and mighty opium!2 Two decades following the publication of these words the First Opium War commences (1839) in which China is martially punished for trying to hinder the British trade of opium to the Chinese people. Though opium, derived from the innocent garden poppy Papavar somniferum, may cradle the keys to Paradise it also clutches the keys to Perdition: its addictive thus potentially ruinous nature is commonly known. Today, partly for these reasons, opiates are mostly illegal without license – stringently so in their most potent forms of morphine and heroin.
    [Show full text]
  • Enzymatic Encoding Methods for Efficient Synthesis Of
    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • A Role for Sigma Receptors in Stimulant Self Administration and Addiction
    Pharmaceuticals 2011, 4, 880-914; doi:10.3390/ph4060880 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review A Role for Sigma Receptors in Stimulant Self Administration and Addiction Jonathan L. Katz *, Tsung-Ping Su, Takato Hiranita, Teruo Hayashi, Gianluigi Tanda, Theresa Kopajtic and Shang-Yi Tsai Psychobiology and Cellular Pathobiology Sections, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, 21224, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]. Received: 16 May 2011; in revised form: 11 June 2011 / Accepted: 13 June 2011 / Published: 17 June 2011 Abstract: Sigma1 receptors (σ1Rs) represent a structurally unique class of intracellular proteins that function as chaperones. σ1Rs translocate from the mitochondria-associated membrane to the cell nucleus or cell membrane, and through protein-protein interactions influence several targets, including ion channels, G-protein-coupled receptors, lipids, and other signaling proteins. Several studies have demonstrated that σR antagonists block stimulant-induced behavioral effects, including ambulatory activity, sensitization, and acute toxicities. Curiously, the effects of stimulants have been blocked by σR antagonists tested under place-conditioning but not self-administration procedures, indicating fundamental differences in the mechanisms underlying these two effects. The self administration of σR agonists has been found in subjects previously trained to self administer cocaine. The reinforcing effects of the σR agonists were blocked by σR antagonists. Additionally, σR agonists were found to increase dopamine concentrations in the nucleus accumbens shell, a brain region considered important for the reinforcing effects of abused drugs.
    [Show full text]
  • Opioids and Nicotine Dependence in Planarians
    Pharmacology, Biochemistry and Behavior 112 (2013) 9–14 Contents lists available at ScienceDirect Pharmacology, Biochemistry and Behavior journal homepage: www.elsevier.com/locate/pharmbiochembeh Opioid receptor types involved in the development of nicotine physical dependence in an invertebrate (Planaria)model Robert B. Raffa a,⁎, Steve Baron a,b, Jaspreet S. Bhandal a,b, Tevin Brown a,b,KevinSongb, Christopher S. Tallarida a,b, Scott M. Rawls b a Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA b Department of Pharmacology & Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA article info abstract Article history: Recent data suggest that opioid receptors are involved in the development of nicotine physical dependence Received 18 May 2013 in mammals. Evidence in support of a similar involvement in an invertebrate (Planaria) is presented using Received in revised form 18 September 2013 the selective opioid receptor antagonist naloxone, and the more receptor subtype-selective antagonists CTAP Accepted 21 September 2013 (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH )(μ, MOR), naltrindole (δ, DOR), and nor-BNI (norbinaltorphimine) Available online 29 September 2013 2 (κ, KOR). Induction of physical dependence was achieved by 60-min pre-exposure of planarians to nicotine and was quantified by abstinence-induced withdrawal (reduction in spontaneous locomotor activity). Known MOR Keywords: Nicotine and DOR subtype-selective opioid receptor antagonists attenuated the withdrawal, as did the non-selective Abstinence antagonist naloxone, but a KOR subtype-selective antagonist did not. An involvement of MOR and DOR, but Withdrawal not KOR, in the development of nicotine physical dependence or in abstinence-induced withdrawal was thus Physical dependence demonstrated in a sensitive and facile invertebrate model.
    [Show full text]
  • PR6 2008.Vp:Corelventura
    Pharmacological Reports Copyright © 2008 2008, 60, 889–895 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Effects of selective s receptor ligands on glucocorticoid receptor-mediated gene transcription in LMCAT cells Gra¿yna Skuza1, Zofia Rogó¿1, Magdalena Szymañska2, Bogus³awa Budziszewska2 1Department of Pharmacology, 2Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Smêtna 12, PL 31-343 Kraków, Poland Correspondence: Gra¿yna Skuza, e-mail: [email protected] Abstract: It has been shown previously that s receptor agonists reveal potential antidepressant activity in experimental models. Moreover, some data indicate s receptor contribution to stress-induced responses (e.g., conditioned fear stress in mice), though the mechanism by which s ligands can exert their effects, remains unclear. Recent studies have indicated that antidepressant drugs (ADs) inhibit glu- cocorticoid receptor (GR) function in vitro. The aim of the present study was to find out whether s receptor ligands are able to di- rectly affect GR action. To this end, we evaluated the effect of s receptor agonists and antagonists on GR function in mouse fibroblast cells (L929) stably transfected with mouse mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) plas- mid (LMCAT cells). For this study, we chose SA 4503, PRE 084, DTG (selective s1 or s1/2 receptor agonists) and BD 1047, SM 21, rimcazole (s receptor antagonists). Fluvoxamine, the selective serotonin reuptake inhibitor with s1/2 receptor affinity, was used for comparison. It was found that SM 21 (at 1, 3, 10 and 30 mM), BD 1047 (3, 10 and 30 mM) rimcazole (10 mM), and fluvoxamine (at 3, 10 and 30 mM) significantly inhibited corticosterone-induced gene transcription, while DTG, SA 4503 and PRE 084 remained inef- fective.
    [Show full text]
  • (Title of the Thesis)*
    Dionysian Semiotics: Myco-Dendrolatry and Other Shamanic Motifs in the Myths and Rituals of the Phrygian Mother by Daniel Attrell A thesis presented to the University of Waterloo in fulfillment of the thesis requirement for the degree of Master of Arts in Ancient Mediterranean Cultures Waterloo, Ontario, Canada, 2013 © Daniel Attrell 2013 Author’s Declaration I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including any required final revisions, as accepted by my examiners. I understand that my thesis may be made electronically available to the public. ii Abstract The administration of initiation rites by an ecstatic specialist, now known to western scholarship by the general designation of ‗shaman‘, has proven to be one of humanity‘s oldest, most widespread, and continuous magico-religious traditions. At the heart of their initiatory rituals lay an ordeal – a metaphysical journey - almost ubiquitously brought on by the effects of a life-changing hallucinogenic drug experience. To guide their initiates, these shaman worked with a repertoire of locally acquired instruments, costumes, dances, and ecstasy-inducing substances. Among past Mediterranean cultures, Semitic and Indo-European, these sorts of initiation rites were vital to society‘s spiritual well-being. It was, however, the mystery schools of antiquity – organizations founded upon conserving the secrets of plant-lore, astrology, theurgy and mystical philosophy – which satisfied the role of the shaman in Greco-Roman society. The rites they delivered to the common individual were a form of ritualized ecstasy and they provided an orderly context for religiously-oriented intoxication.
    [Show full text]
  • Daniel Bovet
    D ANIEL B OVET The relationships between isosterism and competitive phenomena in the field of drug therapy of the autonomic nervous system and that of the neuromuscular transmission Nobel Lecture, December 11, 1957 Putting to good use the vast possibilities which organic synthesis offers, a number of workers have directed their efforts towards applying it to thera- peutics, and have sought to establish the bases of a science of pharmaceutical chemistry, or, more exactly perhaps, the bases of a science of chemical pharmacology worthy of this name. If such an ambitious programme has not yet been fully realized, we are at least justified in recognizing, in the work which has now been in progress for fifty years, the appearance of a few guiding principles whose value has not ceased to assert itself. This is particularly true, for example, in the case of ideas in isosterism and com- petition. The origin of many drugs must be looked for in substances of a biological nature, and in particular in the alkaloids. The elucidation of their structure has been a starting-off point for chemists to synthesize similar compounds. Cocaine, atropine, and morphia are particularly good examples in this respect, since substances which are made like them have shown, clinically, local anaesthetic, antispasmodic, and marked analgesic properties, respective- ly. In each of these cases the physiological properties of the new compound seem to be similar to the compound to which it is structurally related. This has been verified in many other fields, but it is nevertheless evident that in certain cases, molecules which are chemically closely related have very dif- ferent and even antagonistic properties.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Psychedelics Again
    Interview with Sasha T. Shulgin in San Francisco (Lafayette) at his home on July, 11th 2001 Claus: The first time I hit upon your name, was when I became interested in 2,5- dimethoxy-4-methyl-amphetamine (STP, DOM), and found an article authored by yourself. Once I had found your name, I looked for other publications by "A. Shulgin". When I had found a few, I thought it rather strange, that some publications gave a DOW chemical company address, and other articles gave a private address in Shulgin Road, in Lafayette/CA. Alexander: Yes that is interesting, that was around 1968-1970. That was a funny period; I was at Medical School at San Francisco, University of California. I would be wandering through the Haight-Ashbury and everyone around me was stoned on either LSD or who knows what it was called, STP or whatever, that day. And the crowd was turned on: music, love, and happiness. And I was 3 blocks away, memorising the Circle of Willis, and I was wandering about not realizing that the stoned-ness around me that I had invented about 10 years earlier. I did not realize what STP was; I did not know it was DOM. It took 6 months to unravel that. Claus: Do you know that there was a rumour around the day of the festival; the day 2,5-dimethoxy-4-methyl-amphetamine hit the street for the first time, that this was a chemical that came from DOW Chemical Company? Alexander: I never heard that. That makes sense though: I gave a seminar at Johns Hopkins and I talked about the chemical and there were some scraggy people, long hair, beards, stoned.
    [Show full text]
  • Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol Sorscha K
    Grand Valley State University ScholarWorks@GVSU Funded Articles Open Access Publishing Support Fund 9-2018 Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol Sorscha K. Jarman Grand Valley State University, [email protected] Alison M. Haney Grand Valley State University, [email protected] Glenn R. Valdez Grand Valley State University, [email protected] Follow this and additional works at: https://scholarworks.gvsu.edu/oapsf_articles Part of the Chemicals and Drugs Commons ScholarWorks Citation Jarman, Sorscha K.; Haney, Alison M.; and Valdez, Glenn R., "Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol" (2018). Funded Articles. 106. https://scholarworks.gvsu.edu/oapsf_articles/106 This Article is brought to you for free and open access by the Open Access Publishing Support Fund at ScholarWorks@GVSU. It has been accepted for inclusion in Funded Articles by an authorized administrator of ScholarWorks@GVSU. For more information, please contact [email protected]. RESEARCH ARTICLE Kappa opioid regulation of depressive-like behavior during acute withdrawal and protracted abstinence from ethanol ¤ Sorscha K. Jarman, Alison M. Haney , Glenn R. ValdezID* Department of Psychology, Grand Valley State University, Allendale, MI, United States of America ¤ Current address: Department of Psychology, Purdue University, West Lafayette, IN, United States of America * [email protected] a1111111111 a1111111111 a1111111111 a1111111111 Abstract a1111111111 The dynorphin/kappa opioid receptor (DYN/KOR) system appears to be a key mediator of the behavioral effects of chronic exposure to alcohol. Although KOR opioid receptor antago- nists have been shown to decrease stress-related behaviors in animal models during acute ethanol withdrawal, the role of the DYN/KOR system in regulating long-term behavioral OPEN ACCESS changes following protracted abstinence from ethanol is not well understood.
    [Show full text]